Business Description
Immunotech Biopharm Ltd
ISIN : KYG4721A1004
Share Class Description:
HKSE:06978: Ordinary SharesCompare
Compare
Traded in other countries / regions
06978.Hong Kong IPO Date
2020-07-10Description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 2.63 | |||||
Debt-to-EBITDA | -1.4 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.9 | |||||
3-Year EPS without NRI Growth Rate | 22.8 | |||||
3-Year FCF Growth Rate | 24.1 | |||||
3-Year Book Growth Rate | -47.8 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.41 | |||||
9-Day RSI | 55.66 | |||||
14-Day RSI | 54.74 | |||||
6-1 Month Momentum % | -33.41 | |||||
12-1 Month Momentum % | -30.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.05 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -20 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -92.74 | |||||
ROA % | -36.11 | |||||
ROIC % | -29.72 | |||||
ROC (Joel Greenblatt) % | -63.5 | |||||
ROCE % | -44.77 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 9 | |||||
Price-to-Tangible-Book | 11.89 | |||||
EV-to-EBIT | -5.71 | |||||
EV-to-EBITDA | -5.71 | |||||
EV-to-FCF | -10.02 | |||||
Earnings Yield (Greenblatt) % | -17.51 | |||||
FCF Yield % | -11.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunotech Biopharm Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | |||
EPS (TTM) (HK$) | -0.711 | ||
Beta | -0.66 | ||
Volatility % | 47.9 | ||
14-Day RSI | 54.74 | ||
14-Day ATR (HK$) | 0.23914 | ||
20-Day SMA (HK$) | 3.1195 | ||
12-1 Month Momentum % | -30.68 | ||
52-Week Range (HK$) | 2.75 - 5 | ||
Shares Outstanding (Mil) | 514.58 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Immunotech Biopharm Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Immunotech Biopharm Ltd Stock Events
Event | Date | Price(HK$) | ||
---|---|---|---|---|
No Event Data |
Immunotech Biopharm Ltd Frequently Asked Questions
What is Immunotech Biopharm Ltd(HKSE:06978)'s stock price today?
The current price of HKSE:06978 is HK$3.33. The 52 week high of HKSE:06978 is HK$5.00 and 52 week low is HK$2.75.
When is next earnings date of Immunotech Biopharm Ltd(HKSE:06978)?
The next earnings date of Immunotech Biopharm Ltd(HKSE:06978) is .
Does Immunotech Biopharm Ltd(HKSE:06978) pay dividends? If so, how much?
Immunotech Biopharm Ltd(HKSE:06978) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |